Navigation Links
SAFC Pharma to Increase Viral Product Manufacturing Capacity
Date:1/14/2008

$12 Million Expansion for Carlsbad, California Production Site

ST. LOUIS, Jan. 14 /PRNewswire-FirstCall/ -- SAFC(R), a member of the Sigma-Aldrich(TM) group (Nasdaq: SIAL), has announced its plans for a $12 million expansion at its niche biologics production facility in Carlsbad, California. Two new fully segregated state-of-the-art viral product manufacturing suites will be built to employ the latest in disposable bioreactor technologies and enable SAFC Pharma's(TM) viral manufacturing to increase to commercial-scale quantities.

Due to become operational in the second half of 2009, the new suites will add 8,000 sq. ft. of manufacturing space and enable 100 L batch production in stirred tank bioreactors and 1,000 L batch manufacturing in disposable bioreactors. The expansion will add to the current 44,000 sq. ft. site and be Biosafety Level 2 compliant, allowing manipulation of human pathogens.

SAFC Pharma Vice President of Manufacturing and U.S. Operations David Feldker commented, "The 2007 acquisition of Molecular Medicine Bioservices significantly enhanced SAFC Pharma's Biologics offer in viral product manufacturing, including novel vaccines and gene therapies. This expansion will increase our Carlsbad site capabilities from clinical-scale to commercial-scale manufacturing, further demonstrating SAFC's continued commitment to support its customers in the development and manufacturing of complex chemistries and niche biologics."

SAFC Pharma is a trusted leader for development and manufacturing of complex small molecule active pharmaceutical ingredients (API) and biologic drug products for the pharmaceutical and biopharmaceutical industries. This latest facility expansion follows a series of 2007 investment
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
2. A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations.
3. Cantox Announces the Launch of Ashuren Health Sciences Pharmaceutical Division
4. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
5. ViroPharma Provides 2008 Outlook
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
8. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
9. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
10. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
11. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Currently offering a comprehensive portfolio ... Weighing, Rice Lake, and Ohaus, Pipette.com has added ... Sartorius CPA Semi-Micro Balance is ideal for lab ... user-friendly laboratory balance. , Sartorius is a global ... balances are well known for their high performance, ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, announced today ... a Notice of Allowance for a composition of matter ... C. difficile program, SYN-004. This is Synthetic Biologics, ... the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... Oct. 20, 2014 Asterias Biotherapeutics, Inc. ... has signed a Notice of Grant Award (NGA) ... effective October 1, 2014.  The NGA provides for ... the release of additional grant funds pursuant to ... for clinical development of Asterias, product, AST-OPC1. The ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... NeoGenomics, Inc. (OTC,Bulletin Board: NGNM) announced today that it ... May 7, 2008., The Company has scheduled a ... May 7, 2008, at 11:00 AM EDT. Interested investors ... minutes prior to the call. A replay of the ...
... Scientific,Corporation (NYSE: BSX ) announced today that ... issued its ruling in an,arbitration between the Company ... pursuant to the 2005 settlement agreement between,the companies, ... various U.S. and European patents held by Medinol. ...
... LEXINGTON, Mass., May 5 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... Phase III extension study of SUPPRELIN(R) LA (histrelin ... of central,precocious puberty or early onset puberty, at ... This study evaluated the two-year,safety and efficacy of ...
Cached Biology Technology:NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 3Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 2Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 3Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 4Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 5
(Date:10/16/2014)... October 16, 2014 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... technologies including Wocket™, the Smart Wallet, at the 13 ... is a leading global conference on the intersection of ... Mark Anderson , founder and publisher of the ...
(Date:10/15/2014)... University Mainz (JGU) as a full member, ensuring ... a significant nationwide standing in the field of ... Gutenberg University Mainz as a full member of ... and international competition for the best minds and ... proud that Mainz University has been recognized as ...
(Date:10/15/2014)... Geneticist Fred Alt will be awarded the 44th Rosenstiel ... University for his pioneering research exploring the mechanisms of ... and cancer cells. Alt is the second alumnus to ... the Nobel Prize in 2003. , Alt is the ... Genetics at Harvard Medical School and an investigator at ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... that the extremely hot, dry and windy conditions on Black ... rolls, -similar to streamers of wind flowing through the air ... the first of its kind to produce such detailed, high-resolution ... for future fire management and warning systems. The work ...
... is a project that will require the cooperation ... and individuals. The 2012 American Chestnut Summit will ... and industry professionals to share the current state ... reintroduction of this species to eastern forests. The ...
... New Rochelle, NY, August 7, 2012The global market value of ... once therapeutics are approved that actually change the course of ... (GEN). The current therapeutic market is valued at $3 to ... or address the symptoms but do not alter the underlying ...
Cached Biology News:Unusual weather events identified during the Black Saturday bushfires 2GEN reports on recent progress in Alzheimer's research 2
Alexa Fluor 647 anti-mouse Qa-2...
... is the first fully genetically encoded fluorescent ... intracellular hydrogen peroxide (H2O2), one of the ... the basis of yellow fluorescent protein inserted ... protein OxyR (OxyR-RD), HyPer demonstrates submicromolar affinity ...
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: